Wednesday, 17 August 2022

 

 

LATEST NEWS First Of Its Kind Collaboration (Jashn E Kashmir) Between Punjabi And Kashmiri Artists Pulls Youth In The Valley Secrets: The PropheC Drops Captivating Teaser Of Upcoming Track. Video Inside Andhra Pradesh to get Rs 1.54 lakh cr investment in 2 years Drashti Dhami reveals what made her say yes to 'Duranga' Akshay Kumar grooves to 'Main Khiladi Tu Anari' after 28 years for 'Selfiee' Father's friends rape teenage daughter, one arrested in Kerala Kriti Sanon wants Vijay Devarakonda, Kartik Aaryan, Ryan Gosling in her swayamwar Asaduddin Owaisi slams Centre over targeted killings of Kashmiri Pandits Ireland all-rounder Kevin O'Brien retires from international cricket Basavaraj Bommai supports BJP minister after his 'no functioning govt in Karnataka remark Indices end higher for third straight session, Sensex closes at 58,842 Pulkit Bangia calls 'Kumkum Bhagya' life changing break 'Squid Game' wins two prizes at US critics' awards Prateik Babbar, Simi Chahal's 'Tere Bajjon' is an emotional rollercoaster Nitish Kumar calls 1st cabinet meeting to distribute portfolios to ministers On TV, you just get lost : Aly Goni Ranjit Bawa Is Soon To Hit Music Charts With His Debut EP. Shares Details On IG Stories Adal Badal: After Shershaah, Kiara Advani & Sidharth Malhotra To Share Screen In Upcoming Rom-Com Film Sidharth Malhotra finally reveals his 'future plans' with Kiara on 'Koffee With Karan' Defence Minister Rajnath Singh hands over multiple indigenous weapons to Army Kamal Haasan-starrer 'Vikram' completes 75 days in theatres

 

India will have 'approved' vaccine by 2021 Q1: Bernstein Research

Web Admin

Web Admin

5 Dariya News

New York , 27 Aug 2020

India is on course to have an "approved" vaccine within the first quarter of calendar year 2021 and Pune based Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, is well placed to deliver the first vaccine, according to a report out Thursday from Bernstein Research, a top Wall Street research and brokerage firm."Globally, there are four candidates that are close to an approval by the end of the CY2020 or early 2021. Through partnerships India has access to two of those - AZ/Oxford's viral vector vaccine and Novavax's protein sub-unit vaccine with AZ/Oxford's vaccine ahead by a quarter," says the Bernstein report, which IANS has reviewed."With their existing capabilities and capacities SII is best positioned to commercialise one or both of the partnered vaccine candidates depending on approval timing, capacities and pricing."Data from Phase 1 and Phase trials look promising for both these candidates "in terms of safety and the vaccines ability to elicit an immune response". The way things look now, the report indicates that both vaccine candidates "will require two doses to be administered 21/28 days apart".The report strikes an upbeat tone on India's "global capacity equation" and does not foresee "manufacturing scale up challenges".Serum Institute of India, the report says, could supply 600 million doses in 2021 and 1 billion doses in 2022, out of which 400 to 500 million "should be available in India in 2021" in the context of the company's commitments to Gavi The Vaccine Alliance and lower and middle income markets.

The report estimates that vaccine volumes will be split 55:45 between the government and private market."We believe the government channel will have first access to the capacities but also believe there will be a sizable private market. In terms of funding, manpower and delivery infrastructure the Government will struggle to shoulder the burden on its own and we expect the private market to step in and supplement."SII has announced that Gavi will procure vaccines at $3 per dose. The Bernstein report uses that as a benchmark to estimate procurement price to be around $3 a dose for the government and end consumer price of about $6 per dose.Apart from SII, the report lists at least three other Indian pharma companies - Zydus, Bharat Biotech and Biological E - which are working on their own vaccine candidates and are currently in Phase 1 and 2.Between SII, Bharat Biotech, Biological E, and some smaller players, India produces around 2.3 billion doses of various vaccines every year.SII alone is the globally largest manufacturer of vaccines with 1.5 billion doses capacity. Every two out of three children globally gets a shot manufactured by SII.In early August, SII entered into a partnership with Gavi, The Vaccine Alliance and the Bill and Melinda Gates Foundation, to accelerate the manufacture and delivery of up to 100 million doses of COVID-19 vaccines for India and low- and middle-income countries (LMICs).The collaboration pumps upfront capital to SII to help them increase manufacturing capacity now so that, once a vaccine, or vaccines, gains regulatory approval and WHO prequalification, doses can be produced at scale for distribution to India and lower and middle income nations as quickly as the first half of 2021.The overall vaccine market in India is estimated at "$6 billion spread over FY 21-22", according to Bernstein.

 

Tags: Coronavirus , COVID 19 , Novel Coronavirus , India Fights Corona , Fight Against Corona , Stay Home Stay Safe , Stay Home , Corona Virus Updates , Coronavirus Epidemic , Coronavirus Pandemic , Corona virus threat , Corona Outbreak , Serum Institute of India , SII , Bernstein Research

 

 

related news

 

 

 

Photo Gallery

 

 

Video Gallery

 

 

5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2022 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD